Firstly, congratulations to the team at Verona Pharma on their incredible $10bn dollar deal with Merck! And to Actithera on their oversubscribed $75.5M Series A – a great achievement in the current market. Huge congratulations also go to the incomparable Clive Cookson on receiving the Lifetime Achievement Award at the Association of British Science Writers […]
EQT Life Sciences expands the Series B with additional capital, alongside continued support from existing investors, including, Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus, and UPMC Enterprises Basel, Switzerland, December 11, 2024 – Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, announced the successful close of a […]
Financing led by Novo Holdings, including new investment from EQT Life Sciences – LSP Dementia Fund, OrbiMed and SR One with participation from existing investors M Ventures, Sofinnova Partners, GSK Equities Investments Limited and Johnson & Johnson Innovation – JJDC, Inc. Funds will be used to progress lead asset ASN51, an oral small molecule OGA […]
Novo Holdings A/S, a leading global life sciences investor, today announced that it has agreed to acquire Ellab from EQT. Headquartered in Hillerød, Denmark, Ellab (“Ellab”) provides validation and monitoring solutions and services for biotech and pharmaceutical processes. Its solutions and services measure and document parameters such as temperature, pressure and carbon dioxide, which helps […]
